MDK-1654 / Medikine - LARVOL DELTA

MDK1654: A Branched Synthetic Peptide that Activates Both the IL-7 Receptor and the βγc Form of the IL-2/15 Receptor (SITC 2022) - "Conclusions These data indicate that MDK1654 mimics the effect of the non-alpha binding form of IL-2/15 or IL-7, depending on the cell type. To our knowledge, this is the first demonstration of a synthetic peptide with agonist activity for two different cytokine receptors and offers an exciting new modality for cancer immunotherapy."

IO biomarker • Oncology • CD4 • CD8 • IL15 • IL2 • IL7 • STAT5

Medikine Presents Preliminary Results of a Single-Dose Phase 1 Healthy Subject Study of MDK-703, a Peptide-Based Mimetic of Interleukin-7 (IL-7) (Businesswire) - "A second poster presentation detailed preclinical results in peripheral blood monocytes (PBMCs) from healthy donors for MDK-1654, Medikine’s dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINES...In addition to activating both the IL-2/15Rβγc and IL-7Rαγc signaling pathways, MDK-1654 expanded all memory T cells, including CD8 Tscm. It also exhibited additive and complementary effects of IL-2/15Rβγc and IL-7Rαγc signaling among various blood immune cell populations, specifically Tscm, γδT cells, and NK cells...Together, the combined actions of MDK-1654 suggest it could drive deep and durable anti-tumor responses in cancer by activating cells involved in both the adaptive and innate immune systems."

Preclinical • Oncology

Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022) (Businesswire) - "Medikine...announced today that it will deliver two poster presentations at the upcoming Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)....The first poster presentation will highlight preliminary Phase 1 safety, tolerability, and pharmacokinetic/pharmacodynamic data on Medikine’s lead program, MDK-703, an Fc-peptide fusion protein incorporating an IL-7 PEPTIKINE discovered using Medikine’s innovative platform technology. A second poster will detail preclinical data on MDK-1654, Medikine’s dual-acting agonist that incorporates both IL-7 and non-alpha IL-2/15 PEPTIKINEs."

P1 data • Preclinical • Oncology